Awaiting FDA nod, Novartis touts latest data on gene therapy Zolgensma
admin 6th May 2019 Uncategorised 0As Novartis waits for FDA action on its gene therapy Zolgensma, expected this month, the company has rolled out yet another round of data on the spinal muscular atrophy treatment.
More: Awaiting FDA nod, Novartis touts latest data on gene therapy Zolgensma
Source: fierce